Due to the surge in production and sales of intermediates, this pharmaceutical company will achieve a double increase in profit in 2022!

【Pharmaceutical Network Enterprise News】On the evening of January 10, East Asia Pharmaceutical released its 2022 performance report, which is expected to achieve operating income of 1.
180 billion yuan in 2022, a year-on-year increase of 65.
62%; the net profit attributable to the parent was 104 million yuan, a year-on-year increase of 51.
58%; Basic earnings per share were 0.
91 yuan
.
For the reasons for the sharp increase in performance, the company said that there are three main factors, one of which is that the company's new workshop of cefzoxime sodium intermediate was put into use in September 2021, and the production and sales of cefzoxime sodium intermediate in 2022 increased significantly compared with the same period of the previous year; Second, with the gradual recovery of terminal sales of downstream customers, the sales volume of some of the company's products increased compared with the same period of the previous year; Third, the company adopted a new sales strategy to explore the market and achieved results, and the sales volume and price of some products increased
compared with the same period of the previous year.
Cefzoxime sodium is a third-generation cephalosporin drug with broad-spectrum antibacterial effects
.
This variety is a 1 billion-level large variety, and more than 38 manufacturers of this type of drug have been approved in the domestic market, and the competition on the track is fierce
.
At present, no manufacturer of cefzoxime sodium for injection has passed the consistency evaluation, and the industry expects that this type of product will be included in the centralized procurement
within 2-3 years.
At the same time, some securities institutions pointed out that with the replacement of the first and second generation cephalosporin by the third and fourth generation cephalosporins, the market consumption of the entire third generation cephalosporin is expected to grow
steadily.
It is expected that the annual sales scale of cefzoxime sodium will stabilize at about
1.
5 billion during the "14th Five-Year Plan" period.
It is understood that under the continuous increase in market demand for cefzoxime sodium, East Asia Pharmaceutical has been unable to match order demand due to production capacity, resulting in limited product expansion and market development
.
In order to expand production capacity, the company began to expand the cefazoxime sodium intermediate production line project through fundraising and investment in October 2020
.
In September 2021, the project officially entered the production commissioning stage to accelerate the release
of production capacity.
Regarding the benefits brought by the new workshop of cefzoxime sodium intermediates after they are put into production, East Asia Pharmaceutical mentioned in its semi-annual report in 2022 that the company's revenue in the first half of 2022 increased by 55.
14% year-on-year, due to the gradual recovery
of terminal sales of drugs by downstream customers.
Especially in the main business of APIs and intermediates, the company continued to expand production capacity after completing technological transformation, and the trial production of the new workshop of cefazoxime sodium intermediates injected strong momentum
into the company.
It is reported that East Asia Pharmaceutical, which is currently focusing on the upgrading of production capacity of its main business, has a large number of orders
in its hands.
Especially in the stage when the production capacity of the cephalosporin antibiotic market is cleared and cephalosporin intermediates and preparation products are concentrated in high-quality varieties, the industry believes that East Asia Pharmaceutical, as a leading enterprise of chemical APIs and pharmaceutical intermediates in the field of antibacterial, will continue to maintain a rapid growth trend with the release of production capacity
.
According to the data, the main business of East Asia Pharmaceutical is pharmaceutical manufacturing business, and the main products are antibiotics, digestive system, antiviral, cardiovascular, antipyretic and analgesic drugs
。 At present, the antibiotic drugs in production mainly include amoxicillin, clavulanate potassium dispersible tablets, azithromycin dispersible tablets, azithromycin for injection, roxithromycin capsules, cefzoxime sodium for injection, etc.
; Non-antibiotic drugs mainly include digestive system drugs (such as pantoprazole sodium for injection, omeprazole sodium for injection, omeprazole enteric-coated capsules, lansoprazole enteric-coated capsules, etc.
), antiviral drugs (such as ribavirin for injection, acyclovir for injection, acyclovir tablets, ganciclovir for injection, etc
.
), cardiovascular drugs, antipyretic analgesics (such as celecoxib capsules, etc.
).
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.